对“SARS-CoV-2 抑制肺部抗凝和纤维蛋白溶解基因表达”一文的评论回复。
Response to comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.
机构信息
Versiti Blood Research Institute, Department of Cell Biology Neurobiology and Anatomy Medical College of Wisconsin, Milwaukee, United States.
Department of Pathology and Laboratory Medicine and UNC Blood Research Center, Chapel Hill, United States.
出版信息
Elife. 2022 Jan 11;11:e74951. doi: 10.7554/eLife.74951.
Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged based on issues with the samples (Fitzgerald and Jamieson, 2022). We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.
在 SARS-CoV-2 大流行早期，我们比较了住院 COVID-19 患者和没有 COVID-19 的对照患者的转录组数据。我们发现 COVID-19 患者肺部中促凝和纤维蛋白溶解基因表达的变化（Mast 等人，2021 年）。这些发现基于样本存在的问题受到了质疑（Fitzgerald 和 Jamieson，2022 年）。我们根据这一挑战重新审视了我们之前的分析，发现这些新的分析支持我们最初的结论。
Zotero 插件